Altered dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil containing chemotherapy

André B. P. van Kuilenburg, Heinz-Josef Klumpen, Anneke M. Westermann, Lida Zoetekouw, Piet J. M. Bakker, Henk-Jan Guchelaar, Dick J. Richel

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Dihydropyrimidine dehydrogenase (DPD) plays a pivotal role in the metabolism of 5-fluorouracil (5FU). In patients treated with capecitabine or 5FU combined with other chemotherapeutic drugs, DPD activity in peripheral blood mononuclear cells was increased in patients experiencing grade I/II neutropenia. In contrast, decreased DPD activity proved to be associated with grade I/II dermatological toxicity, including hand-foot syndrome. Thus, patients with a low-normal or high-normal DPD activity proved to be at risk of developing mild toxicity upon treatment with 5FU-based chemotherapy, demonstrating the important role of DPD in the etiology of toxicity associated with 5FU and the catabolites of 5FU. Copyright © Taylor & Francis Group, LLC.
Original languageEnglish
Pages (from-to)726-732
JournalNucleosides, Nucleotides and Nucleic Acids
Volume27
Issue number6-7
DOIs
Publication statusPublished - 2008
Externally publishedYes

Cite this